Moya Bio
Research - Ness Ziyyona, Center District, Israel
Moya Bio Employees
Moya Bio Details
MOYA Bio is a startup biotech company developing novel E1 inhibitors for solid and hematological malignancies. Scientific Approach - The clinical success of proteasome inhibitors (e.g., bortezomib or carfilzomib) has piqued interest in targeting other components of the Ubiquitin-Proteasome System as well as closely related Ubiquitin-Like (UBL) pathways. Among these, antagonism of E1 enzymes, which instigate the different UBL cascades, has been highlighted as a promising therapeutic approach in cancer. MOYA Bio has developed a series of novel proprietary E1 antagonists that target specific UBL pathways and posses significant anti-cancer activity, which are currently under preclinical development.
